Abstract
Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitopes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an immunosuppressive tumor microenvironment. Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 207-212 |
Number of pages | 6 |
Journal | Current Opinion in Immunology |
Volume | 24 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2012 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology